Anaplastic Lymphoma Kinase Inhibitors-a Review of Anticancer Properties, Clinical Efficacy, and Resistance Mechanisms

Overview

Journal Front Pharmacol

Date 2023 Nov 13

PMID 37954850

Authors

Kajetan Kielbowski

Justyna Zychowska

Rafal Becht

Affiliations

Soon will be listed here.

Abstract

Fusions and mutations of anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor, have been identified in several neoplastic diseases. Rearranged ALK is a driver of tumorigenesis, which activates various signaling pathway associated with proliferation and survival. To date, several agents that target and inhibit ALK have been developed. The most studied ALK-positive disease is non-small cell lung cancer, and three generations of ALK tyrosine kinase inhibitors (TKIs) have been approved for the treatment of metastatic disease. Nevertheless, the use of ALK-TKIs is associated with acquired resistance (resistance mutations, bypass signaling), which leads to disease progression and may require a substitution or introduction of other treatment agents. Understanding of the complex nature and network of resistance mutations may allow to introduce sequential and targeted therapies. In this review, we aim to summarize the efficacy and safety profile of ALK inhibitors, describe off-target anticancer effects, and discuss resistance mechanisms in the context of personalized oncology.

Citing Articles

ALK in cancer: from function to therapeutic targeting.

Voena C, Ambrogio C, Iannelli F, Chiarle R Nat Rev Cancer. 2025; .

PMID: 40055571 DOI: 10.1038/s41568-025-00797-9.

diaPASEF-Powered Chemoproteomics Enables Deep Kinome Interaction Profiling.

Woods K, Rantso T, Chan A, Sapre T, Mastin G, Maguire K bioRxiv. 2024; .

PMID: 39605566 PMC: 11601655. DOI: 10.1101/2024.11.22.624841.

Epithelioid inflammatory myofibroblastic sarcoma with exceptionally long response to lorlatinib-a case report.

Becht R, Kielbowski K, Zychowska J, Poncyljusz W, Lanocha A, Kozak K Ther Adv Med Oncol. 2024; 16:17588359241298489.

PMID: 39574496 PMC: 11580051. DOI: 10.1177/17588359241298489.

Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy.

Chen C, Sun Z, Wang Z, Shin S, Berrios A, Mellors J Antibodies (Basel). 2024; 13(2).

PMID: 38804307 PMC: 11130946. DOI: 10.3390/antib13020039.

Ge F, Dai X, Qiu Y, Liu X, Zeng C, Xu X Acta Pharmacol Sin. 2024; 45(6):1252-1263.

PMID: 38360931 PMC: 11130210. DOI: 10.1038/s41401-024-01230-x.

References

Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H . Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014; 74(5):1023-8. DOI: 10.1007/s00280-014-2578-6. View

Shaw A, Yeap B, Mino-Kenudson M, Digumarthy S, Costa D, Heist R . Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27(26):4247-53. PMC: 2744268. DOI: 10.1200/JCO.2009.22.6993. View

Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S . Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer. NPJ Precis Oncol. 2023; 7(1):12. PMC: 9879975. DOI: 10.1038/s41698-023-00350-7. View

Cao Z, Zhang J, Guo M, Shao B, Wei X, Li S . Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects. Bioorg Chem. 2023; 136:106563. DOI: 10.1016/j.bioorg.2023.106563. View

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

Watanabe S, Sakai K, Matsumoto N, Koshio J, Ishida A, Abe T . Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory -Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501). Cancers (Basel). 2023; 15(1). PMC: 9818646. DOI: 10.3390/cancers15010204. View

Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H . Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res. 2012; 18(22):6219-26. DOI: 10.1158/1078-0432.CCR-12-0392. View

Shi Y, Fang J, Hao X, Zhang S, Liu Y, Wang L . Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal Transduct Target Ther. 2022; 7(1):25. PMC: 8795197. DOI: 10.1038/s41392-021-00841-8. View

Hoy S . Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC. Drugs. 2021; 81(2):267-275. DOI: 10.1007/s40265-020-01449-y. View

10.

Sabir S, Yeoh S, Jackson G, Bayliss R . EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients. Cancers (Basel). 2017; 9(9). PMC: 5615333. DOI: 10.3390/cancers9090118. View

11.

Pan Y, Liu X, Zhang W, Wang W, Wang H, Luo L . Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion. Lung Cancer. 2023; 181:107233. DOI: 10.1016/j.lungcan.2023.107233. View

12.

Shiraishi T, Yamasaki K, Kidogawa M, Shingu T, Ujimiya F, Jotatsu T . Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene. Intern Med. 2023; 62(21):3215-3221. PMC: 10686730. DOI: 10.2169/internalmedicine.1164-22. View

13.

Chaudhuri A, Chabon J, Lovejoy A, Newman A, Stehr H, Azad T . Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017; 7(12):1394-1403. PMC: 5895851. DOI: 10.1158/2159-8290.CD-17-0716. View

14.

Matsuura Y, Mun M, Shintani Y, Okami J, Ito H, Ohtsuka T . Features of anaplastic lymphoma kinase rearrangement in early-stage lung cancer: Analysis of a nationwide Japanese database. J Surg Oncol. 2023; 128(5):916-924. DOI: 10.1002/jso.27384. View

15.

Murray B, Zhai D, Deng W, Zhang X, Ung J, Nguyen V . TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations. Mol Cancer Ther. 2021; 20(9):1499-1507. PMC: 9398166. DOI: 10.1158/1535-7163.MCT-21-0221. View

16.

Kimbara S, Takeda K, Fukushima H, Inoue T, Okada H, Shibata Y . A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib. Jpn J Clin Oncol. 2014; 44(9):868-71. DOI: 10.1093/jjco/hyu069. View

17.

Berko E, Witek G, Matkar S, Petrova Z, Wu M, Smith C . Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma. Nat Commun. 2023; 14(1):2601. PMC: 10163008. DOI: 10.1038/s41467-023-38195-0. View

18.

Sato-Nakai M, Kawashima K, Nakagawa T, Tachibana Y, Yoshida M, Takanashi K . Metabolites of alectinib in human: their identification and pharmacological activity. Heliyon. 2017; 3(7):e00354. PMC: 5506877. DOI: 10.1016/j.heliyon.2017.e00354. View

19.

Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J . Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. Clin Cancer Res. 2015; 21(17):4014-21. DOI: 10.1158/1078-0432.CCR-15-0016. View

20.

Friboulet L, Li N, Katayama R, Lee C, Gainor J, Crystal A . The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014; 4(6):662-673. PMC: 4068971. DOI: 10.1158/2159-8290.CD-13-0846. View